Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid receives funding from US strategic investor

Cellmid’s consumer health subsidiary Advangen sells hair growth products.
evolis hair growth products
Advangen sells hair growth products in Australia, Japan and the U.S

Cellmid Limited (ASX:CDY) has received $1 million in the form of a strategic investment from US based investor, Dennis Eck.

Notably, the shares to be placed with Eck are priced at $0.38, representing no discount to the last Thursday's closing price.

Eck is a professional investor with 40 years’ senior management experience in the retail sector including beauty.

Cellmid board to utilise new investor’s retail experience

Eck will be advising Cellmid’s board on its US retail strategy in 2018.

The company continues to progress its strategy to access the premium retail market for its evolis® branded FGF5 inhibitor hair loss products.

Maria Halasz, chief executive, said: “It is very exciting to secure support from a strategic investor of Dennis Eck’s industry experience and wisdom.

“We are looking forward benefiting from his insights into retail."

The expansion of evolis® anti-aging hair care products

In July 2016 Cellmid embarked on a US market strategy for its evolis® branded hair loss and anti-aging hair care products.

Since then, Cellmid has developed the evolis® Professional branded anti-aging hair care products.

It has successfully completed manufacture of the range and secured prestige retail distribution with Neiman Marcus and Soft Surroundings in the US.

READ: Cellmid secures second US partner to sell évolis hair growth products

Cellmid recently secured its second premium retail partner in the US, Soft Surroundings.

Soft Surroundings owns 59 stores across the US and will sell Cellmid’s évolis® Professional product range.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use